A six-month prospective, randomized, double-blind, placebo-controlled study to determine efficacy of daily nicotinamide riboside and pterostilbene in adults with non-alcoholic fatty liver disease
Latest Information Update: 13 Sep 2022
At a glance
- Drugs Nicotinamide-riboside/pterostilbene (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- 13 Sep 2022 New trial record
- 09 Sep 2022 Results published in the Hepatology